Submission of Outcome of the Board Meeting held on 13th November, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals held a board meeting on 13 November 2025 with two key outcomes. First, Independent Director Ms. Monam Kapoor (DIN: 09278005) resigned due to pre-occupation and personal commitments, effective close of business on 13 November 2025. She also stepped down from the Audit, Nomination & Remuneration, and Stakeholders Relationship Committees. Second, the board approved the unaudited standalone financial results for Q2 FY26 (quarter ended 30 September 2025). Revenue from operations surged to Rs. 3,638.89 lakhs in Q2 (vs Rs. 2,235.12 lakhs in Q1 FY26 and just Rs. 395.66 lakhs in Q2 FY25), with H1 FY26 total income at Rs. 5,874.26 lakhs versus Rs. 457.26 lakhs a year earlier. Net profit for H1 FY26 was Rs. 54.03 lakhs (EPS Rs. 0.44 basic). Share capital increased to Rs. 1,448 lakhs from Rs. 995 lakhs, indicating a fresh equity raise.
The director exit is routine and personal, but leaves a vacancy on three key board committees that the company will need to fill. The financials show very strong top-line growth year-on-year, though profit margins remain thin. For shareholders, the bigger takeaways are the sharp revenue jump (possibly reflecting a business pivot since the company was renamed from Trimurthi Limited) and the equity dilution from the recent capital raise.